Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.45 |
| ▸ | PRKCA | P17252 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29534067 | 0.99 | CDK1 (0.44) | CDK1PRKCANPC1EGFRERBB2 | |
| SCHEMBL22480240 | 0.94 | SRC (0.45) | CDK1PRKCANPC1EGFRCCNA2 | |
| Hydrochloric Acid SCHEMBL29533833 | 0.94 | SRC (0.44) | CDK1PRKCANPC1EGFRCCNA2 | |
| SCHEMBL6574741 | 0.80 | CDK1 (0.67) | CDK1PRKCANPC1EGFRCCNA2 | |
| SCHEMBL6574743 | 0.80 | CDK1 (0.67) | CDK1PRKCANPC1EGFRCCNA2 | |
| SCHEMBL6574902 | 0.74 | CDK1 (0.71) | CDK1PRKCAEGFRCDK2 | |
| SCHEMBL6574904 | 0.74 | CDK1 (0.71) | CDK1PRKCAEGFRCDK2 | |
| SCHEMBL6576169 | 0.74 | CDK1 (0.71) | CDK1PRKCANPC1EGFRLMNA | |
| SCHEMBL6578444 | 0.74 | CDK1 (0.71) | CDK1PRKCANPC1EGFRLMNA | |
| SCHEMBL6576950 | 0.74 | CDK1 (0.71) | CDK1PRKCAEGFRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152036-A1 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA | ACADEMIA SINICA (TW) | 2022-05-19 | — | — | US | disclosed |
| WO-2020198367-A1 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND β-THALASSEMIA | ACADEMIA SINICA (TW) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152036-A1 | COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND ß-THALASSEMIA | HBG1, HBG2, HBB | CDK1 1915/4885PRKCA 844/4885NPC1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.